雷洛昔芬与法匹拉韦药物联用对法匹拉韦体内药代动力学的影响研究
张力婧1,2 杨孟孟2 包欢1 李飞1

1辽宁石油化工大学 石油化工学院，辽宁抚顺，113001；

2军事医学研究院国家安全特需药品全国重点实验室，北京，100850；

摘要：法匹拉韦（Favipiravir，T705）在体内易受醛氧化酶（AO）介导而氧化失活，极大限制了其临床应用价值。雷洛昔芬（Raloxifene，RAL）作为一种强效AO抑制剂，能抑制T705的代谢失活过程，提高其体内暴露水平。本研究目的探究RAL预给药对小鼠体内T705药代动力学的影响，采用液相色谱—串联质谱（LC-MS/MS）法对小鼠全血中T705进行定量分析，并基于二室模型计算药代动力学参数。研究结果表明，RAL与T705药物联用策略显著提高T705的体内生物利用度。

关键词：法匹拉韦；雷洛昔芬；醛氧化酶；药物联用；药代动力学；生物利用度

参考文献

[1]赵旭,周辛波,钟武,等.抗病毒药物——法匹拉韦[J]. 临床药物治疗杂志,2015,13(04):16-20.

[2]Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea [J]. Plos Medicine, 2016, 13(3).

[3]Furuta Y, Gowen B B, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor [J]. Antiviral Research, 2013, 100(2): 446-54.

[4]Wang YM, Zhong W, Salam A, et al. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza [J]. Ebiomedicine, 2020, 62.

[5]Banyard A C, Mansfield K L, Wu G H, et al. Re-evaluating the effect of Favipiravir treatment on rabies virus infection [J]. Vaccine, 2019, 37(33): 4686-93.

[6]Doi Y, Hibino M, Hase R, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 [J]. Antimicrobial Agents and Chemotherapy, 2020, 64(12).

[7]Naydenova K, Muir K W, Wu L F, et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP [J]. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118(7).

[8]Coelho C, Mahro M, Trincao J, et al. The First Mammalian Aldehyde Oxidase Crystal Structure INSIGHTS INTO SUBSTRATE SPECIFICITY [J]. Journal of Biological Chemistry, 2012, 287(48): 40690-702.

[9]Garattini E, Fratelli M, Terao M. The mammalian aldehyde oxidase gene family. Hum Genomics. 2009 Dec; 4(2):119-30.

[10]Terao M, Garattini E, Romao M J, et al. Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes [J]. Journal of Biological Chemistry, 2020, 295(16): 5377-89.

[11]Garattini E, Terao M. The role of aldehyde oxidase in drug metabolism [J]. Expert Opinion on Drug Metabolism & Toxicology, 2012, 8(4): 487-503.

[12]Hayden F G, Lenk R P, Epstein C, et al. Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza [J]. Journal of Infectious Diseases, 2023, 230(2): e395-e404.

[13]Obach R S, Huynh P, Allen M C, et al. Human liver aldehyde oxidase: Inhibition by 239 drugs [J]. Journal of Clinical Pharmacology, 2004, 44(1): 7-19.

[14]Mota C, Diniz A, Coelho C, et al. Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case [J]. J Med Chem, 2021, 64(17): 13025-37.